Scientists have created artificial cells that mimic biological cells by responding to a chemical change in their surroundings.
Synthetic biologists seek to create new life with forms and functions not seen in nature. Although scientists are a long way from making a completely artificial life form, they have made semi-synthetic organisms that have an expanded genetic code, allowing them to produce never-before-seen proteins.
Bosch has agreed to sell its packaging machinery division to private equity firm CVC Capital Partners for an undisclosed sum.
After a review of clinical data from the Generation Program studies, Novartis, Amgen and Banner Alzheimer’s Institute have decided to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer’s Prevention Initiative Generation Program.
AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC).